Drug intelligence / Profile preview

DMTA07

Development stage: Unknown
Lead developer: TSH Biopharm
Administration: Oral

Overview

DMTA07 is an investigational drug studied in combination with amlodipine for the treatment of mild to moderate essential hypertension. The exact molecular identity, mechanism of action, and detailed pharmacological properties of DMTA07 are not disclosed in publicly available sources. It has been tested in clinical trial settings to determine its antihypertensive efficacy and safety profile when used as an adjunct to amlodipine, suggesting a primary cardiovascular application. Developer information associated with trial registration points to Tshbiopharm (Taiwan).[1][3]

Other names: DMTA07DMTA-07DMTA 07

Beyond the preview

Go deeper on DMTA07.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DMTA07.

Explore the full profile